/ Source: The Associated Press
Drug delivery technology company Generex Biotechnology Corp. said Monday it inked a deal to conduct clinical trials with Beijing Daopei Hospital in China.
The studies will involve immunotherapies and the company's RNAi stimulation methods.
Generex said RNAi technology is being viewed as a possible improvement over current therapies, such as chemotherapy for cancer, which uses a broad stroke method, destroying the cancer cells but damaging healthy cells in the process. RNAi targets specific genes.
Shares of Generex rose 5 cents, or 3 percent, to $1.73 on the Nasdaq Stock Market in afternoon trading. The stock has traded between $1.25 and $3.92 over the last 52 weeks.